Antiphospholipid antibodies, thrombin and LPS activate brain endothelial cells and Ras-dependent pathways through distinct mechanisms

被引:23
作者
Aronovich, R
Gurwitz, D
Kloog, Y
Chapman, J [1 ]
机构
[1] Tel Aviv Univ, Sackler Fac Med, Dept Physiol & Pharmacol, IL-69978 Ramat Aviv, Israel
[2] Tel Aviv Univ, Sackler Fac Med, Dept Human Genet & Mol Med, IL-69978 Ramat Aviv, Israel
[3] Tel Aviv Univ, George S Wise Fac Life Sci, Dept Neurobiochem, IL-69978 Tel Aviv, Israel
[4] Tel Aviv Univ, Sackler Fac Med, Dept Neurol, IL-69978 Ramat Aviv, Israel
关键词
antiphospholipid syndrome; brain; endothelial cells; ERK; thrombin;
D O I
10.1016/j.imbio.2005.10.010
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Background: The antiphospholipid syndrome (APS) commonly affects the central nervous system through mechanisms that may include small vessel pathology and activation of thrombin. Antiphospholipid antibodies (aPL) activate endothelial cells but the specific activation of brain vascular endothelial cells (BVEC) and the receptors and signaling pathways involved have not been fully characterized. Objective: To examine whether aPL, the inflammatory stimulant lipopolysacharide (LPS) and thrombin activate BVECs through a Ras-dependent pathway. Methods: Rat BVEC (G8) were grown to confluence on 24-well plates. IgG was purified from 8 APS patients on a protein G column. Phosphorylation of ERK in the BVEC was measured by immunoblot utilizing a specific antibody. Results: Significant phosphorylation of ERK was measured following exposure of the cells to LPS and thrombin and this was blocked by the Ras inhibitor farnesylthiosalicylate (FTS). aPL IgG (1: 100 relative to serum) from 7/8 patients also induced phosphorylation of ERK. Conclusions: Activation of the Ras-ERK pathway is an effect of both APS IgG and thrombin. This pathway is potentially amenable to drugs such as FTS and may serve as a therapeutic target in APS. (C) 2005 Elsevier GmbH. All rights reserved.
引用
收藏
页码:781 / 788
页数:8
相关论文
共 68 条
[11]   Antiphospholipid antibodies induce monocyte chemoattractant protein-1 in endothelial cells [J].
Cho, CS ;
Cho, ML ;
Chen, PP ;
Min, SY ;
Hwang, SY ;
Park, KS ;
Kim, WU ;
Min, DJ ;
Min, JK ;
Park, SH ;
Kim, HY .
JOURNAL OF IMMUNOLOGY, 2002, 168 (08) :4209-4215
[12]   Ras antagonist farnesylthiosalicylic acid (FTS) reduces glomerular cellular proliferation and macrophage number in rat Thy-1 nephritis [J].
Clarke, HC ;
Kocher, HM ;
Khwaja, A ;
Kloog, Y ;
Cook, HT ;
Hendry, BM .
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2003, 14 (04) :848-854
[13]   Cerebral haemostasis and antiphospholipid antibodies [J].
Connor, P ;
Hunt, BJ .
LUPUS, 2003, 12 (12) :929-934
[14]  
DELPAPA N, 1995, CLIN EXP RHEUMATOL, V13, P179
[15]  
DelPapa N, 1997, ARTHRITIS RHEUM-US, V40, P551
[16]  
DelPapa N, 1997, AM J REPROD IMMUNOL, V38, P212
[17]   NFκB is an essential intermediate in the activation of endothelial cells by anti-β2-glycoprotein 1 antibodies [J].
Dunoyer-Geindre, S ;
de Moerloose, P ;
Galve-de Rochemonteix, B ;
Reber, G ;
Kruithof, EKO .
THROMBOSIS AND HAEMOSTASIS, 2002, 88 (05) :851-857
[18]  
Dunoyer-Geindre S, 2001, THROMB HAEMOSTASIS, V85, P903
[19]   Fluvastatin inhibits up-regulation of tissue factor expression by antiphospholipid antibodies on endothelial cells [J].
Ferrara, DE ;
Swerlick, R ;
Casper, K ;
Meroni, PL ;
Vega-Ostertag, ME ;
Harris, EN ;
Pierangeli, SS .
JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2004, 2 (09) :1558-1563
[20]   Inhibition of the thrombogenic and inflammatory properties of antiphospholipid antibodies by fluvastatin in an in vivo animal model [J].
Ferrara, DE ;
Liu, XW ;
Espinola, RG ;
Meroni, PL ;
Abukhalaf, I ;
Harris, EN ;
Pierangeli, SS .
ARTHRITIS AND RHEUMATISM, 2003, 48 (11) :3272-3279